WELL Health reveals plans to acquire Cycura’s services division

By Nikita Chaurasia  Date: 2020-07-10

WELL Health reveals plans to acquire Cycura’s services division

 

  • The acquisition would elevate WELL Health's cybersecurity program across the technology and healthcare sectors 
  • WELL Health would build a strong portfolio of companies and products/services as part of its capital allocation initiative

WELL Health Technologies Corp., a Canada-based venture 50 firm, has recently announced that it is planning to sign a definitive asset purchase deal with Cycura Inc., a private corporation that offers customized defensive cyber security solutions.

According to the terms of the agreement, WELL Health will be acquiring entire assets of Cycura's Services Division, which evidently offers several cybersecurity offerings like security-focused code reviews, penetration and vulnerability testing, cybersecurity training, incident response services, technical due diligence services, and cybersecurity M&A advisory. 

Reportedly, the total consideration payable by WELL Health in coherence with this transaction leads up to almost $2.55 million. However, the final valuation is still subject to certain adjustments, time-based payments, and holdbacks.

Apparently, Cycura offers its cybersecurity services to numerous high-profile firms operating across multiple industry verticals in Canada such as telemedicine, a collection of healthcare-related clients concentrating on mental health along with health insurance and benefits business.

Speaking on the move, Hamed Shahbazi, Chairman and CEO, WELL Health, said that the company’s overarching objective has always been to allocate capital to opportunities and themes that benefit from healthcare digitization. As a result, WELL Health considers cybersecurity as an impelling opportunity for the firm's capital allocation initiative owing to the burgeoning growth in the industry and the quality of revenues.

Moreover, WELL Health is dedicated to offering patient data privacy and cyber security protection across every major business including Electronic Medical Record (EMR), primary care, digital health solutions, and telehealth. The company has been working with Cycura’s team of experts for over a year now and are delighted to integrate their proficiency in data protection, privacy, and cyber security within WELL Health, added Shahbazi. 

Source Credit: https://www.newswire.ca/news-releases/well-health-to-acquire-cycura-s-services-division-to-protect-personal-health-information-879186332.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...